Muscarinic receptors are a family of five proteins found throughout your body that respond to acetylcholine, one of the nervous system’s primary chemical messengers. They control a wide range of functions, from how fast your heart beats to how your brain forms memories. These receptors are the main way your parasympathetic nervous system communicates with organs like the heart, lungs, bladder, and digestive tract, making them a major target for dozens of common medications.
How Muscarinic Receptors Work
Muscarinic receptors belong to a larger class of proteins called G protein-coupled receptors. Each one is a single protein that threads through the cell membrane seven times, with part of it exposed on the outside of the cell (where acetylcholine binds) and part on the inside (where it triggers a chain reaction). When acetylcholine locks onto the outer portion, the receptor changes shape and activates a G protein inside the cell. That G protein then sets off a cascade of secondary signals that ultimately change how the cell behaves.
This design makes muscarinic receptors fundamentally different from the other major type of acetylcholine receptor, called nicotinic receptors. Nicotinic receptors are ion channels: when acetylcholine binds, a pore opens almost instantly and ions rush through, producing a rapid electrical signal. That speed is essential at the junction between nerves and skeletal muscles, where a millisecond delay could impair movement. Muscarinic receptors trade speed for versatility. Because they work through a secondary messenger system rather than a direct ion channel, they can produce slower, more sustained, and more varied responses, including changes in gene activity that last well beyond the initial signal.
The Five Subtypes
There are five muscarinic receptor subtypes, labeled M1 through M5. They split into two functional groups based on which internal signaling pathway they activate.
M1, M3, and M5 (the odd-numbered subtypes) activate a pathway that ultimately increases calcium release inside cells. This triggers effects like muscle contraction in the gut and airways, or enhanced signaling between neurons in the brain.
M2 and M4 (the even-numbered subtypes) work through a different pathway that reduces levels of a molecule called cAMP, a common internal signal. The practical result is generally inhibitory: slowing the heart, dampening nerve activity, or dialing down the release of other chemical messengers.
M1: Cognition and Memory
M1 receptors are concentrated in the cerebral cortex and hippocampus, brain regions central to learning, memory, and higher-order thinking. They play a significant role in cognitive function, which is why drugs with strong anticholinergic effects (those that block muscarinic receptors) can cause confusion and memory problems, particularly in older adults.
M2: Heart Rate Control
M2 receptors sit primarily in the heart’s atria and its natural pacemaker, the sinoatrial node. When activated, they counteract the stimulating influence of the sympathetic (“fight or flight”) nervous system, reducing both heart rate and the force of atrial contractions. This is the main mechanism by which vagus nerve activity slows the heart.
M3: Smooth Muscle and Glands
M3 receptors are the workhorses of the parasympathetic system’s “rest and digest” functions. They’re found in smooth muscle throughout the body, including the airways, gastrointestinal tract, bladder, and blood vessels. Activating M3 receptors constricts the bronchi, contracts the gut and gallbladder, narrows the pupils, and dilates blood vessels. M3 receptors are also present in sweat glands, where they drive sweat production even though those glands technically receive signals from the sympathetic nervous system.
In the bladder, M3 receptors are the predominant system controlling the detrusor muscle, the layer of smooth muscle responsible for bladder contraction during urination. Overactive bladder, a condition marked by involuntary bladder contractions during the filling phase, is treated primarily with drugs that block M3 receptors.
M4: Dopamine Regulation
M4 receptors are expressed most heavily in the substantia nigra, a brain region involved in movement and reward, with lower levels in the cortex and hippocampus. Studies in mice lacking M4 receptors suggest this subtype plays a key role in regulating dopamine, the neurotransmitter tied to motivation, movement, and several psychiatric conditions.
M5: Cerebral Blood Flow
M5 is the least understood subtype. In the periphery, M5 receptors appear to help dilate arteries supplying the brain. Their role within the central nervous system itself remains unclear.
Muscarinic vs. Nicotinic Receptors
Both muscarinic and nicotinic receptors respond to acetylcholine, but they serve different purposes and sit in different locations. Nicotinic receptors are found at the neuromuscular junction (where nerves signal skeletal muscles to move) and in the ganglia of the autonomic nervous system, where they relay signals between neurons. Muscarinic receptors, by contrast, are found on the end organs themselves: the heart, lungs, gut, bladder, eyes, glands, and brain.
The practical difference is timing and duration. Nicotinic receptors produce fast, brief electrical events suited for rapid muscle contractions. Muscarinic receptors produce slower, longer-lasting changes suited for regulating organ function over seconds or minutes. Your body uses both in sequence: a nerve signal passes through a nicotinic relay in the ganglion, then the second nerve in the chain releases acetylcholine onto muscarinic receptors on the target organ.
Drugs That Target Muscarinic Receptors
Because muscarinic receptors influence so many organ systems, a surprisingly large number of medications work by either blocking or activating them.
Drugs that block muscarinic receptors (called muscarinic antagonists or anticholinergics) are used across a range of conditions:
- COPD and asthma: Inhaled antagonists like ipratropium relax the airways by blocking M3 receptors on bronchial smooth muscle.
- Overactive bladder: Antagonists targeting M3 receptors reduce involuntary bladder contractions.
- Parkinson’s disease: Anticholinergic drugs help restore the balance between acetylcholine and dopamine in the brain.
- Motion sickness and nausea: Scopolamine patches work by blocking muscarinic receptors in brain areas that trigger nausea.
- Organophosphate poisoning: Atropine, a potent muscarinic blocker, is the frontline treatment for poisoning by pesticides or nerve agents that flood the body with acetylcholine.
Many common medications also have anticholinergic effects as side effects rather than intended actions. Older antihistamines, certain antidepressants, and some antipsychotics all block muscarinic receptors to varying degrees. This is why these drugs can cause dry mouth, blurred vision, constipation, and difficulty urinating, even though those aren’t the effects they were prescribed for.
What Happens When Muscarinic Receptors Are Blocked
When muscarinic receptors across the body are blocked at once, whether by medication overdose or by natural toxins found in plants like belladonna and jimson weed, the result is a recognizable pattern of symptoms that medical professionals remember with a classic mnemonic: “blind as a bat” (dilated pupils and blurred vision), “dry as a bone” (no sweating or saliva), “hot as a hare” (elevated body temperature from inability to sweat), “red as a beet” (flushed skin), “mad as a hatter” (confusion and hallucinations), and “fast as a racehorse” (rapid heart rate).
Each symptom maps directly to a muscarinic receptor losing its normal function. Pupils dilate because M3 receptors in the eye can no longer constrict them. The heart races because M2 receptors can no longer slow it. Sweating stops because M3 receptors on sweat glands are silenced. Hallucinations and confusion arise because M1 receptors in the brain are blocked. This pattern, sometimes called anticholinergic toxidrome, can progress from peripheral symptoms to agitated delirium, then stupor and coma in severe cases.
Muscarinic Receptors and Brain Health
The concentration of M1 receptors in brain areas responsible for memory and cognition has made them a significant focus in neurodegenerative disease research. In Alzheimer’s disease, the neurons that produce acetylcholine are among the earliest to degenerate, leaving muscarinic receptors with less and less of their natural activator. Current Alzheimer’s medications that inhibit the breakdown of acetylcholine work partly by keeping more of this dwindling supply available to stimulate remaining muscarinic receptors.
M4 receptors, with their role in dopamine regulation, have drawn attention in the context of conditions where dopamine signaling goes awry, including Parkinson’s disease and schizophrenia. The challenge has always been developing drugs selective enough to target one subtype without affecting the others, since all five subtypes share a very similar binding site for acetylcholine. Advances in understanding the subtle structural differences between subtypes are gradually making more selective drugs possible.